Nov 15, 2021 / 02:30PM GMT
Oliver Maier - Bayer Aktiengesellschaft - Head of IR
Good afternoon, and good morning. It's a great pleasure to be with you today, and I welcome you to our 2021 Investor Webinar for Pharma. As announced in October, at the Crop Science webinar, we are planning a series of these events in an effort to keep you appraised of the key developments and milestones across the group. Today, we are showcasing one of the most important launch assets from our pharma pipeline, brand name KERENDIA or finerenone. We will be sharing today 4 things: First, details of the clinical profile; second, then the differentiated nature of KERENDIA; third, how it fits into the treatment landscape; and fourth, our current plans for life cycle management.
With me on the webinar today are Christian Rommel, our Head of R&D at Pharma; and Sebastian Guth, Head of Commercial Operations, Americas in our Pharmaceutical division. We will begin the webinar with some prepared remarks from Christian and Sebastian, followed by about roughly ballpark 30 minutes of Q&A. So pretty much the same setup as we've had in the last webinar
Bayer AG Finerenone Investor Webinar Transcript
Feb 12, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers